Clinical Trials Logo

Colorectal Neoplasms clinical trials

View clinical trials related to Colorectal Neoplasms.

Filter by:

NCT ID: NCT02605044 Terminated - Clinical trials for Metastatic Colorectal Cancer

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Start date: January 2014
Phase: Phase 3
Study type: Interventional

The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.

NCT ID: NCT02597075 Terminated - Clinical trials for Metastatic Colorectal Cancer

Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy

Start date: March 17, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to assess whether a structured physical activity program (PA) during palliative chemotherapy improves progression-free survival (PFS) and/or patient-reported outcomes (ESAS-r) in patients with metastatic colorectal cancer.

NCT ID: NCT02581709 Terminated - Breast Neoplasms Clinical Trials

An Intervention Programme to Reduce Cognitive Impairment Due to Cancer

Start date: May 2016
Phase: N/A
Study type: Interventional

The goal of this research study is to test the feasibility of an intervention programme to reduce cognitive impairment due to cancer treatment. The investigators want to find out how acceptable the intervention and procedures are for cancer patients.

NCT ID: NCT02581059 Terminated - Colorectal Cancer Clinical Trials

Efficacy of Ginseng for Patients on Regorafenib

Start date: April 2016
Phase: Phase 2
Study type: Interventional

This is a randomized, multi-center phase II study of ginseng in colorectal cancer patients treated with regorafenib to determine if ginseng will reduce fatigue in this patient population and improve adherence to regorafenib. Ninety (90) subjects will be enrolled and randomized using a 2:1 allocation, with 60 subjects enrolled in the regorafenib + ginseng group and 30 enrolled in the regorafenib + no ginseng group.

NCT ID: NCT02577588 Terminated - Clinical trials for Colorectal Carcinoma

Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer

ATACC
Start date: May 1, 2016
Phase: Phase 1
Study type: Interventional

The study "Phase I trial of Adoptive T cell Therapy with Activated P53 specific T cells for Treatment of Advanced Colorectal Cancer" is an open label, single arm trial.

NCT ID: NCT02568046 Terminated - Clinical trials for Metastatic Colorectal Cancer

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Start date: March 15, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2a study investigating the safety and efficacy of Sym004, an investigational medicinal product (IMP), in combination with FOLFIRI (chemotherapy) when administered every second week (Q2W).

NCT ID: NCT02560740 Terminated - Colorectal Cancer Clinical Trials

A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy

Start date: March 2016
Phase: N/A
Study type: Interventional

Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive, enduring, and often irreversible condition featuring pain, numbness, tingling and sensitivity to cold in the hands and feet (sometimes progressing to the arms and legs) that afflicts between 30 and 40 percent of patients undergoing chemotherapy. American Society of Clinical Oncology (ASCO) guidance on The Journal of Clinical Oncology (JCO, 2014 April 14) does not recommend any prophylaxis regimen for CIPN. PerOx Quench has unique membrane protection and anti-oxidative function as a special food, that's why to try to explore its preventive effects on CIPN prevention induced by Oxaliplatin for colorectal cancer or gastric cancer chemotherapy.

NCT ID: NCT02559024 Terminated - Clinical trials for Colorectal Neoplasms

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

Start date: March 14, 2016
Phase: Phase 1
Study type: Interventional

This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before surgical treatment.

NCT ID: NCT02538627 Terminated - Colorectal Cancer Clinical Trials

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Start date: August 2015
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.

NCT ID: NCT02511756 Terminated - Clinical trials for Metastatic Colorectal Cancer

Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)

AVA-CTP
Start date: July 2015
Phase: N/A
Study type: Interventional

The primary objective of this study is to investigate the anti-angiogenic effect of bevacizumab measured by CTP as a predictive marker for efficacy measured by progression-free survival (PFS) in mCRC patients under first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy